| Autor: |
Urbain, J. L. C., Shore, S. K., Vekemans, M. C., Cosenza, S. C., DeRiel, K., Patel, G. V., Charkes, N. D., Malmud, L. S., Reddy, E. P |
| Zdroj: |
European Journal of Nuclear Medicine and Molecular Imaging; June 1995, Vol. 22 Issue: 6 p499-504, 6p |
| Abstrakt: |
Based on the specificity of the Watson-Crick base pairing formation, antisense deoxyoligonucleotides have been used to inhibit the expression of oncogenes in various cancer cells. Activation of an oncogene by means of amplification leads to an increased, detectable amount of the mRNA transcript in the cytoplasm. The aim of this study was to demonstrate that cells which are expressing a particular mRNA transcript do preferentially and specifically retain the antisense probe targeting that mRNA. Using a mouse plasmacytoma cell line (MOPC315) which produces high levels of IgA heavy chain mRNA, a control mouse pre B cell line (70ZJ3B), a human mammary cell line (MCF7) which expresses the erbB2 or neu oncogene, MOPC315 cells as neu-negative controls, and antisense DNA oligonucleotides complementary to the 5' region of the mRNAs and the sense sequence, we have shown that there is a preferential, specific retention of the IgA andneu antisense sequence in MOPC315 and MCF7 cells, respectively. We have further demonstrated that this retention is time and concentration dependent with a maximum at 24 h. We conclude that cancer cells which express a particular oncogene are suitable targets for radiolabeled antisense deoxyoligonucleotides directed toward the oncogene transcript. This work and recent developments in the antisense field lead to the expectation of a new class of radiopharmaceuticals with unique specificity. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink